Guillermo Garcia-Manero, MD

Articles

Dr Garcia-Manero on the Association Between Hemoglobin Levels and QOL in Lower-Risk MDS

September 16th 2024

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.

Dr Garcia-Manero on the Investigation of Luspatercept Dose Levels in Low-Risk MDS

August 12th 2024

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept dose levels in patients with low-risk myelodysplastic syndrome who require red blood cell transfusions.

Dr Garcia-Manero on the Impact of Luspatercept on Hematopoietic Lineages in Lower-Risk MDS

July 1st 2024

Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS.

Managing AEs Associated with HMA Treatment

January 25th 2024

Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.

Treating CMML and AML with HMAs

January 18th 2024

An overview of how HMAs are being used to treat CMML and their use in combination with other therapies for patients with AML.

The Role for HMAs in Lower-Risk MDS

January 18th 2024

An expert discusses data supporting the use of HMAs in the treatment of lower-risk MDS.

The Impact of Oral HMA Treatment Options on QOL

January 11th 2024

A review of the benefits of oral HMA treatments in the management of MDS, and the impact on a patient's quality of life.

Real-World Use for Oral HMAs

January 11th 2024

An expert discusses the real-world impact of hypomethylating agents for the treatment of patients with MDS.

Available and Emerging Oral HMAs

January 4th 2024

Guillermo Garcia-Manero, MD, provides a high-level overview of the effectiveness of oral HMA agents in the treatment of intermediate- and high-risk MDS.

Treating Intermediate- and High-Risk MDS

January 4th 2024

The role of HMAs in the treatment of patients with intermediate- and high-risk MDS.

Efficacy and Safety of Luspatercept versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naïve Patients with Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Full Analysis of the COMMANDS Trial

December 19th 2023

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

Diagnosing and Managing Myelodysplastic Syndrome

December 19th 2023

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs). In this episode, gain insights about MDS risk stratification and prognosis, and why it is important to treat early.

Dr Garcia-Manero on the Investigation of Luspatercept in Transfusion-Dependent MDS

September 12th 2023

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept vs epoetin alfa in patients with erythropoiesis-stimulating agent-naïve, lower-risk myelodysplastic syndromes and disease-related anemia who requires red blood cell transfusions.

Efficacy and Safety Results From the COMMANDS Trial: A Phase 3 Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive Transfusion-Dependent Patients With Lower-Risk Myelodysplastic Syndromes

June 16th 2023

Guillermo Garcia-Manero, MD, reviews data from the COMMANDS trial comparing the efficacy and safety of luspatercept to epoetin alfa in patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on blood transfusions and have not previously received erythropoiesis-stimulating agents (ESAs).